A YEAR OF ENGAGEMENT: OUR ANNUAL REPORT FOR 2023



PRESIDENT'S MESSAGE



By Alexia Sena, President of the Board

n 2023, GHA was proud to <u>celebrate</u> its 15-year <u>anniversary</u> and look back at its evolution both in terms of highlights, advocacy impact but also strategic and organisational development. Everything about those 15

years show that investing in health is a smart political strategy. We have dedicated our work and mandate to showing French, European and international decision makers that more investments but also better and more efficient political strategies are needed to deliver health for all.

Even in a post-COVID world, there needs to be constant reminders about the unequivocal value of efficiently addressing health inequalities. GHA remains mobilised, together with civil society and other partners in the health sector to live up to current and upcoming global health challenges.

Looking back at this <u>journey</u>, I would like to personally thank all current and former staff, GHA Board members as well as our donors who made this possible and helped us reflect and evolve into this dynamic and impactful family-sized organisation we are today. I am also particularly thankful to our civil society partners worldwide, particularly those part of the <u>ACTION Global Health Advocacy</u> network with whom we ensure not only national but also regional and global impact.

KEY RESULTS IN 2023

Access Denied: What happens when Big Pharma

is in the driver's seat

lobal Health Advocates, together with STOPAIDS, commissioned a report series exploring how a lack of transparency in the pharmaceutical industry and the European Union harmed public health outcomes. Through legal and investigative research, the two reports outlined the circumstances in which COVID-19 vaccine negotiations took place and explored the level of influence of Big Pharma at EU level - which is significant and indicative of a severe lack of transparency and a clear imbalance of power between the two.



The final report of the European Parliament's special COVI Committee echoed key concerns on transparency, accountability, access and the critical role of global solidarity.

The reports were submitted by a Green MEP as annexes alongside evidence in the ECJ <u>case</u> brought by 5 green MEPs on vaccine contract transparency.



GHA held a successful <u>webinar</u> in January to launch the key findings, with speakers Marc Botenga MEP, Dr Olga Gurgula (Brunel University) and Dimitri Eynikel (MSF Access Campaign).



 Media coverage for the report included pieces in <u>Euractiv</u>, APM health Europe and Politico. The report series highlights the <u>EU's position of weakness</u> vis-à-vis the pharmaceutical industry, includes a <u>review of COVID-19 vaccine contracts</u> and provides a set of key recommendations for greater transparency.



2. Redefining the role of MDBs in health financing to achieve health for all


he COVID-19 pandemic highlighted the urgent need for collective action and for strengthening the global health architecture. In particular, further attention needs to be paid to Multilateral Development Banks (MDBs) as they play a more important part in providing health financing. What role should they play? Are their interventions effective enough? Do they truly improve access to health care for the most vulnerable populations?



One of GHA's key recommendations was a call for MDBs to increase collaboration with one another as well as with Global Health Initiatives. GHA was extremely pleased to witness the launch of the Health Impact Investment Platform between the WHO and a selected number of MDBs during the New Global Financing Pact Summit, which aims at strengthening primary health care.

At the World Bank
Spring meetings,
the paper provided
discussion material
for informal meetings
with several key actors,
including French and
EU representatives, World
Bank staff and CSO partners.





GHA <u>released an op-ed signed</u> by 115 NGOs worldwide, urging President Emmanuel Macron to take concrete actions for global health equity at the Summit.

on the role of MDBs in financing health for all opens the discussion on the unique contribution they could have in the global health landscape.



An <u>abridged</u> version of the paper was released prior to the New Global Financing Pact Summit held in Paris in June, which was later <u>handed</u> to the French <u>Minister of Finance</u> during the event.



Ensuring an ambitious new French global health strategy

2023 was a pivotal year for international solidarity and development in France with the adoption of a new global health strategy for 2023-2027. This was the result of months of engagement by GHA, alongside partners from the Collectif Santé Mondiale and Coordination Sud, through various working groups supporting the renewal of the strategy process. As the text was being finalised, GHA also advocated – with success – for a high-level political backing of the launch of the new strategy.



Release of a new ambitious and exhaustive strategy document for the 2023-2030 period.

As advocated by GHA and partners, an accountability framework is being developed for the strategy to help monitor its implementation and impact.



A welcome referral to strengthen France's action in global health

Following the release of the <u>Cour des comptes'</u> <u>conclusions</u> on French global health ODA, GHA <u>called</u> for increased funding for the implementation of the future strategy.



In October, GHA took part in the <u>official launch event</u> of the global health strategy alongside three French Ministers: those of European and Foreign affairs, Health & Solidarity, and Higher education & Research, and the Director-General of the WHO.


Increasing French and EU mobilisation for TB R&D

ith the second United Nations High-Level meeting (UN HLM) on TB organised in New York in September and The Union Conference hosted by France in November, 2023 was a critical year to stress the need to accelerate the global fight against tuberculosis.




Adoption of a new ambitious TB Political Declaration at the UN HLM on TB with a <u>stronger positioning</u> on the need to guarantee financial and social protections for TB-affected communities, the explicit recognition of access to innovation as a fundamental human right and the inclusion of time-bound specific targets for TB R&D funding.

High-level French participation at the UN HLM on TB: the French Minister of Health called on its counterparts to redouble collective efforts to end TB by 2030 and reaffirmed that "France would always answer present when it comes to TB R&D and support to international organisations".



Position paper released in August, calling on France and the EU to strengthen their political and financial support for TB R&D.

French MPs joined the global call for increased TB R&D investments. Specifically, the rapporteur for the official development assistance mission questioned the French government regarding its actions in support of TB R&D on the occasion of the opening of The Union Conference.



Ahead of The Union Conference, Global Health Advocates published a call in October signed by almost 200 international CSO partners and researchers asking France to increase support to TB R&D.



Blog series on tuberculosis R&D released in June, interviewing 3 experts from civil society and the world of research.

GHA moderated a media briefing on TB R&D, aimed at French journalists ahead of The Union Conference, leading to the release in November of an article in leading French newspaper Le Monde.



5. health and international solidarity A year of Parliamentary commitment to global

n 2023. Global Health Advocates achieved a significant milestone in its advocacy work with MPs, with the launch of the informal Parliamentary Club Unis pour la santé - the first and only of its kind in France, just months after the latest legislative elections in France. The club aims to raise awareness. inform and support French members of Parliament on global health and international solidarity issues.



Around 20 parliamentarians actively participated in our events while nearly 200 MPs disseminated our advocacy calls through various channels.

5 MPs co-signed a letter to President Macron calling for the strengthening of sexual and reproductive rights following the study trip to Senegal.



Global Health Advocates organised several delegations as well as informal meetings between MPs and global health leaders. A new focus explored in 2023 was the nexus between health and climate and the One Health approach.

MPs' mobilisation included a push to reinforce the financial transaction tax (FTT) in the 2024 French Budget Bill - the vote of the National Assembly Finance Commission was an important step forward on the subject, even if the clause was ultimately discarded in the final version of the bill.






the challenges posed by global health threats, which was presented at the French National Assembly on June 5th.


OUR RESOURCES

1 306 232€

total budget in 2023

RESOURCE ALLOCATION IN 2022





OUR 2023 FINANCIAL PARTNERS



BILL & MELINDA GATES foundation

European Artificial Intelligence & Society Fund







Thank you to our partners

GHA

Created in 2011, Global Health Advocates is a French NGO whose mission is to carry out political advocacy in France and with the EU institutions, in partnership with civil society, to ensure policies and resources are effectively addressing health inequalities.

FIND US



(2) +33 9 81 85 33 16

 $igspace \operatorname{\mathsf{info@ghadvocates.org}}$

Website: www.ghadvocates.eu

www.actionsantemondiale.fr

X France: @GHAFrance

X EU: @GHABrussels

LinkedIn: Global Health Advocates



